Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10885092 | 0.86 | TSHR (0.81) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL27482122 | 0.85 | ALDH1A1 (0.82) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL247684 | 0.85 | ALDH1A1 (0.81) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL10889030 | 0.85 | ALDH1A1 (0.81) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL10885387 | 0.85 | ALDH1A1 (0.81) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL4251896 | 0.85 | TSHR (0.62) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL27770561 | 0.85 | ALDH1A1 (0.81) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| Allylbenzene SCHEMBL27338356 | 0.85 | ALDH1A1 (0.71) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL513788 | 0.84 | TSHR (0.77) | TSHRMAPK1CYP3A4TP53ALDH1A1 | |
| SCHEMBL6670151 | 0.84 | TSHR (0.76) | TSHRMAPK1CYP3A4TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280279-A1 | SOAP AND SURFACTANT FREE SHAVE LOTION COMPOSITION | L'OREAL (FR) | 2018-10-04 | — | — | US | claimed |
| US-20240225975-A9 | AN IMPROVED LONG WEARING SUNSCREEN COSMETIC | BASF SE (DE) | 2024-07-11 | — | — | US | disclosed |
| WO-2024141896-A1 | PECTIN BASED FIRMING SYSTEM FOR ANTIAGING SKIN CARE AND MAKEUPS | L'OREAL (FR) | 2024-07-04 | — | — | WO | disclosed |
| EP-3870309-B1 | MINERAL SUNSCREEN COMPOSITIONS WITH IMPROVED EFFICACY | OREAL (FR) | 2024-07-03 | — | — | EP | disclosed |
| EP-4392144-A1 | SUNSCREEN COMPOSITION COMPRISING: A METAL OXIDE, SPF ACTIVE INGREDIENT; AND ONE OR MORE SPF ENHANCEMENT COMPONENT COMPRISING A PHOTOSTABILIZER, AN ANTIOXIDANT, OR A COMBINATION THEREOF | Colgate-Palmolive Company (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240207164-A1 | PECTIN BASED FIRMING SYSTEM FOR ANTIAGING SKIN CARE AND MAKEUPS | L'OREAL (FR) | 2024-06-27 | — | — | US | disclosed |
| US-20240130940-A1 | AN IMPROVED LONG WEARING SUNSCREEN COSMETIC | BASF SE (DE) | 2024-04-25 | — | — | US | disclosed |
| US-11957769-B2 | Polyhydroxy fullerene sunscreen active agents and compositions | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4294534-A1 | AN IMPROVED LONG WEARING SUNSCREEN COSMETIC | BASF SE (DE) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023224944-A1 | SUNSCREEN COMPOSITION COMPRISING: A METAL OXIDE, SPF ACTIVE INGREDIENT; AND ONE OR MORE SPF ENHANCEMENT COMPONENT COMPRISING A PHOTOSTABILIZER, AN ANTIOXIDANT, OR A COMBINATION THEREOF | COLGATE-PALMOLIVE COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-8652449-B1 | Sunscreen compositions having synergistic combination of UV filters | L'OREAL (FR) | 2014-02-18 | — | — | US | disclosed |
| US-8557227-B2 | Sunscreen compositions having synergistic combination of UV filters | L'OREAL S.A. (FR) | 2013-10-15 | — | — | US | disclosed |
| US-8545891-B1 | Sunscreen compositions having synergistic combination of titanium dioxide filters | L'OREAL (FR) | 2013-10-01 | — | — | US | disclosed |
| WO-2013078197-A1 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS | L'OREAL S.A. (FR) | 2013-05-30 | — | — | WO | disclosed |
| US-20130129650-A1 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS | L'OREAL S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130129649-A1 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION FO UV FILTERS | L'OREAL S.A. (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20090209637-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-20 | — | — | US | disclosed |
| EP-2056782-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | Merck Patent GmbH (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025368-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-03-06 | — | — | WO | disclosed |
| CN-101095648-A | Dibenzoylmethane sunscreens photostabilized with arylalkyl amide or ester compounds | OREAL (FR) | 2008-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209637-A1 | USE OF CHROMEN-4-ONE DERIVATIVES | CBR1, CYP46A1, CCR8 | TSHR 1588/4885MAPK1 2192/4885CYP3A4 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.